MedTrace Logo

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

NCT06322667 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2026-01-23

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

Conditions

Interventions

OTHER

No Intervention

This is a non-interventional study.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-14
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06322667 on ClinicalTrials.gov